Nassim Kamar

Nassim Kamar is a French nephrologist and transplant physician associated with the Department of Nephrology, Dialysis, and Organ Transplantation at CHU Rangueil, Toulouse University Hospital. In the volume, he appears both as a contributor to the chapter on Treatment of Hepatitis C Virus Infection after Kidney Transplantation and as a principal investigator whose serial clinical studies shape the discussion of post-transplant liver disease. His importance lies in replacing a simple narrative of inevitable deterioration with a more discriminating account: many HCV RNA-positive kidney recipients remain histologically stable, while particular patients develop severe fibrosis, fibrosing cholestatic hepatitis, or immune-complex renal disease requiring focused treatment.

Identity and Clinical Setting

Nassim Kamar works at the intersection of nephrology, dialysis, transplantation, hepatology, and virology. The chapter in which he is named includes Lionel Rostaing, Hugo Weclawiak, and Jacques Izopet, with the authorship linking clinical transplantation to laboratory virology and INSERM research. This setting is essential to Kamar’s role: the subject is not Hepatitis C considered only as a liver infection, but as a systemic disease capable of affecting the kidney, the renal allograft, and long-term patient survival.

The wider medical framework explains why Kamar’s work matters. HCV infection can produce hepatic, autoimmune, dermatological, and renal disease, and chronic infection in patients with chronic kidney disease must therefore be screened, staged, and treated within a coordinated nephrology and transplantation pathway. Diagnosis depends on anti-HCV antibodies together with detectable HCV RNA, while liver biopsy remains the reference method for staging active infection in many transplant candidates. Kamar’s studies extend that framework beyond the initial evaluation by asking what happens to liver histology and renal function after transplantation and immunosuppression.

Research on Liver Fibrosis After Transplantation

Kamar’s most consequential contribution is the longitudinal study of liver fibrosis after kidney transplantation. In a cohort of 51 anti-HCV-positive, HCV RNA-positive kidney transplant recipients, patients underwent liver biopsies every three to four years. The series included two biopsies for all 51 patients, three for 42, and four for 9, creating a repeated histological record rather than a single snapshot. The overall rate of fibrosis progression was 0.09 ± 0.03 Metavir units per year.

The results divided the recipients into three clinically distinct trajectories. Liver fibrosis remained stable in 21 patients, progressed in 21, and regressed in 10. Progression and regression were gradual rather than abrupt, making serial assessment valuable for identifying the minority whose disease was becoming dangerous. Higher ferritin levels and hepatosiderosis were associated with fibrosis. Kamar also identified the initial fibrosis stage and high diversification of the HVR-1 region of the HCV genome between transplantation and the first follow-up biopsy as independent factors associated with regression.

This work complicates earlier reports that kidney transplantation accelerated HCV-related liver injury. Other evidence had suggested faster progression in transplant recipients than in patients with normal renal function or those remaining on dialysis, but Kamar’s findings showed that many HCV RNA-positive kidney recipients experienced little progression, with changes in Metavir score similar to those observed in HCV RNA-positive dialysis patients and lower than those in HCV RNA-positive patients with normal renal function. More than six years of follow-up, including a mean of three serial post-transplant liver biopsies, supported the same general conclusion. Even so, approximately 20% developed severe liver fibrosis, and Kamar’s later synthesis judged that, more than ten years after renal transplantation, HCV-related histological harm affected fewer than half of patients.

The practical consequence is a selective rather than automatic approach to post-transplant antiviral therapy. Sequential biopsies can locate the patients who develop severe fibrosis and may benefit from pegylated interferon plus ribavirin. Treatment is also relevant when fibrosing cholestatic hepatitis appears, because that condition can be rapidly life-threatening. The evidence therefore turns surveillance into an active clinical instrument: stability supports continued observation, while a documented adverse trajectory changes the balance toward treatment.

Treatment Studies and Their Limits

Kamar also investigated ribavirin monotherapy in HCV-positive kidney transplant recipients. In the first large study, 16 treated patients were compared with 32 matched untreated patients. Ribavirin began at 1,000 mg daily and was adjusted according to hemoglobin levels over a planned one-year course. Treatment lowered liver enzyme and serum creatinine levels, and existing proteinuria decreased or disappeared in treated patients. Yet HCV viremia did not change, and the apparent biochemical improvement did not translate into better liver histology.

The treatment’s toxicity exposed the special constraints imposed by impaired renal function. Hemoglobin levels fell dramatically despite substantial recombinant erythropoietin use, reaching a median erythropoietin requirement of 20,000 IU per week, and ribavirin had to be stopped in three cases. Liver fibrosis progressed significantly, while the inflammation score did not improve. Ribavirin was associated with increased ferritin and intrahepatic iron deposition, together with reduced transferrin and total iron-binding capacity. Kamar’s work thus distinguishes improved laboratory enzymes from genuine virologic or histological benefit and emphasizes that drug accumulation may require dose adaptation in kidney transplant recipients.

In a separate open pilot study, eight HCV-positive renal transplant recipients with chronic active hepatitis and raised alanine aminotransferase levels received amantadine at 200 mg daily for six months. Amantadine reduced alanine aminotransferase activity from 100 ± 9 to 71 ± 17 IU/l, but it did not reduce HCV viremia, did not significantly improve aspartate aminotransferase activity, and produced no significant histological change. Clinical and biological tolerance was good, but the treatment was judged ineffective against the infection itself.

Kamar also contributed to the evaluation of ribavirin with or without amantadine. In the randomized comparison, seven patients received ribavirin at 1,000 mg daily, eight received ribavirin at 1,000 mg plus amantadine at 200 mg daily, and 26 received no therapy for 12 months. The active regimens produced no significant advantage in liver enzymes, HCV viremia, liver histology, or renal parameters. Anemia limited treatment, caused premature withdrawal, and led to widespread use of recombinant erythropoietin. A creatinine clearance above 50 ml/min was the strongest predictor of tolerability. These findings narrowed the plausible role of older post-transplant regimens and reinforced the need to reserve treatment for clearly high-risk disease.

Severe Complications and Renal Manifestations

Kamar’s clinical framework also encompasses fibrosing cholestatic hepatitis, a rare but grave complication of HCV infection under immunosuppression. In one series of 259 HCV-infected renal transplant recipients, four patients developed the condition, an incidence of 1.5%. All were receiving steroids, cyclosporine, and azathioprine. The syndrome appeared a mean of 11.5 months after transplantation and was marked by hyperbilirubinemia, very high alkaline phosphatase and gamma-glutamyltransferase levels, only mild aminotransferase abnormalities in comparison, and high serum HCV RNA. Biopsy showed diffuse fibrosis, leukocyte infiltration, and varying cholestasis. Two patients developed subfulminant liver failure and died two and three months after biopsy; another required liver transplantation.

A second series demonstrated how quickly the complication could emerge, with liver dysfunction appearing one to four months after transplantation and histological diagnosis following three to eleven months later. All four patients were HCV RNA-positive at their first biopsy, with high viral loads; three had genotype 1b and one had genotype 3a. After diagnosis, immunosuppression was drastically reduced. Two died from sepsis and liver failure at 16 and 18 months, while the patients who seroconverted after transplantation showed marked improvement, confirmed histologically in one case. Similar patients were successfully treated with interferon, supporting the view that antiviral therapy may be justified when the disease becomes fulminant rather than merely biochemical.

Another important complication is cryoglobulinemia-associated membranoproliferative glomerulonephritis. In a report of seven patients, five HCV-positive, the disorder produced impaired renal function long after transplantation, de novo nephrotic syndrome in five patients, severe hypertension in five, nephritic syndrome in one, and increased serum creatinine in one. Weekly rituximab, given at 375 mg/m2 for two to four weeks, dramatically improved renal parameters. Nephrotic syndrome entered sustained remission in three cases, nephritic syndrome disappeared in one, and two others showed improvement; cryoglobulins cleared sustainably in six. The benefit was tempered by severe infectious complications in two patients, illustrating the narrow therapeutic margin created by post-transplant immunosuppression.

Clinical Significance and Legacy

Kamar’s research gives the post-transplant HCV problem a time scale and a set of decision points. It supports eradication before transplantation whenever possible, because interferon after transplantation increases the risk of renal allograft rejection and because pre-transplant viral clearance reduces the likelihood of HCV-related glomerulonephritis after transplantation. At the same time, his longitudinal evidence resists treating every HCV RNA-positive recipient as destined for rapid liver failure. Most patients in the biopsy cohorts had stable or improved histology, while a smaller group required intensified surveillance and targeted therapy.

That balance is Kamar’s central contribution. He treats the liver biopsy not as a ceremonial confirmation of disease but as a repeated record of change; he treats aminotransferase improvement as insufficient evidence of cure; and he separates ordinary chronic infection from fibrosis, fibrosing cholestatic hepatitis, and cryoglobulinemia-associated renal injury. His work consequently helps organize a clinical policy in which pre-transplant clearance is preferred, post-transplant interferon is approached cautiously, sequential biopsies identify dangerous progression, and rituximab is considered for severe immune-complex glomerular disease despite the risk of infection. In the volume’s broader account of Hepatitis C, Kamar stands for evidence that is longitudinal, organ-spanning, and alert to both therapeutic promise and therapeutic harm.